10 February 2016
Company name: Sosei Group Corporation Listing: Tokyo Stock Exchange Security code: 4565 URL http://www.sosei.com/
Representative: ShinichiTamura
Representative Executive Officer, CEO
Contact person:
Hidetoshi Torami
Executive Vice President, CFO Tel:+81-03-5210-3290
Scheduled date of security report filing: | 10 February 2016 | Scheduled date of dividend payments: | -- |
Supplementary materials for financial results: | -- | ||
Financial results briefing session: | -- |
(Rounded down to nearest million yen)
(1) Consolidated operating results (cumulative) | (Percentages are shown as year-on-year changes) |
Consolidated results for Q3 FY2015 (from 1 April 2015 to 31 December 2015)
Revenue
Operating income
Net income before income taxes
Net income
Net income attributable to owners of the parent company
Total comprehensive income
Q3 FY2015
Million yen
%
Million yen
%
Million yen
%
Million yen
%
Million yen
%
Million yen
%
7,741
713.7
3,449
--
2,754
618.2
2,217
745.5
2,293
774.7
2,299
241.7
Q3 FY2014
951
(48.2)
16
(98.2)
383
(60.4)
262
(72.8)
262
(72.8)
673
(42.9)
Net income per share - basic
Net income per share - diluted
Q3 FY2015
Yen
Yen
155.03
153.69
Q3 FY2014
19.06
18.87
(2) Consolidated financial position
Total assets
Total equity
Equity attributable to owners of the parent company
Ratio of equity attributable to owners of the parent company to total assets
Q3 FY2015
Million yen
Million yen
Million yen
%
48,342
29,849
29,684
61.4
FY2014
43,800
14,894
14,653
33.5
Dividends
Dividends per share
End Q1
End Q2
End Q3
Year end
Total
FY2014
Yen
Yen
Yen
Yen
Yen
-
0.00
-
10.00
10.00
FY2015
-
0.00
-
FY2015 (E)
0.00
0.00
(Note) Revision to the latest dividend forecasts: None
Forecast for the FY2015 (from 1 April 2015 to 31 March 2016)
(Percentages are shown as year-on-year changes)
Revenue | Operating income | Net income before income taxes | Net income attributable to owners of the parent company | Net basic earnings per share | |||||
FY2015 | Million yen | % | Million yen | % | Million yen | % | Million yen | % | Yen |
11,732 | 219.6 | 5,899 | 432 | 5,915 | 332.8 | 6,047 | 975.0 | 439.02 |
(Note) Revision to the latest financial forecasts: None
Notes
Changes in the number of significant subsidiaries in this consolidated cumulative quarter (changes of specified subsidiaries affecting the scope of consolidation): None
Changes in accounting policies, changes in accounting estimates
Changes in accounting policies required by IFRS: None
Changes due to changes in accounting policies other than those of item 1: None
Changes in accounting estimates: None
Q3 FY2015
16,823,384
shares
FY2014
13,774,000
shares
Q3 FY2015
-
shares
FY2014
-
shares
Q3 FY2015
14,795,198
shares
Q3 FY2014
13,755,548
shares
Number of common shares issued
Number of shares issued at the end of financial period (including treasury shares)
Number of treasury shares at the end of financial period
Average number of shares issued during financial period (cumulative total)
Implementation status of financial audit
The audit procedures of the financial statements pursuant to the Financial Instruments and Exchange Law have been completed.
Explanation regarding the appropriate use of forecasts of business results and other points to be noted (Note concerning forward-looking statements)
The financial forecast is based on judgments and estimates that have been prepared on the basis of information available as at the
time of disclosure of this material. The actual business results may differ materially from the forecasts due to various factors.
Contents of Attached Materials
1. Analysis of Operating Results and Financial Position | 4 |
1) Analysis of operating results | 4 |
2) Analysis of financial position | 8 |
3) Earnings forecast | 9 |
2. Matters related to summary information (notes) | 9 |
1) Changes in the number of significant subsidiaries in this consolidated cumulative quarter | 9 |
2) Changes in accounting policies and changes in accounting estimates | 9 |
3. Consolidated Financial Statements (IFRS) | 10 |
1) Consolidated statement of financial position | 10 |
2) Consolidated statement of comprehensive income | 11 |
3) Consolidated statement of changes in equity | 12 |
4) Consolidated statement of cash flow | 13 |
5) Notes related to going concern assumptions | 14 |
6) Segment information | 14 |
Analysis of operating results
- Current term operating results
The Group pursues pharmaceutical research and development mainly through its subsidiaries based in Japan and the UK. The main source of its revenue comes from the development milestones and royalties from the licensees and the sales from its pharmaceutical products. Overall expenses have increased as Heptares Therapeutics Ltd. ("Heptares"), acquired in February 2015, is now included in the Group's results.
The Group recorded the following consolidated cumulative financial results for Q3 2015.
Consolidated operating results
(JPY Million)
Cumulative Q3 FY2014 | Cumulative Q3 FY2015 | Change | |
Revenue | 951 | 7,741 | 6,789 |
Gross profit | 905 | 7,741 | 6,835 |
Operating income (loss) | 16 | 3,449 | 3,432 |
Net income (loss) | 262 | 2,217 | 1,954 |
Revenue and gross profit
Revenue in this consolidated cumulative quarter totalled 7,741 million yen, an increase of 713.7% compared to the previous financial year. This was mainly due to milestones and increased royalty revenue from Seebri® (NVA237*) and Ultibro® (QVA149*), and receipt of upfront payments associated with the licensing of the Heptares pipeline.
Operating income
In this consolidated cumulative quarter the Group recorded operating income of 3,449 million yen, an increase of 3,432 million yen from the comparative period of the previous financial year. This is mainly due to increased revenue and gross profit (referred above).
Net income
In this consolidated cumulative quarter the Group recorded net income of 2,217 million yen, an increase of 1,954 million yen from the comparative period of the previous financial year. This was mainly because while operating income increased, there was an accrual of interest expenses related to borrowings, as well as income tax expenditure.
* Seebri®,Ultibro® and Breezhaler® are the registered trademarks of Novartis AG.
Sosei Group Corporation issued this content on 10 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 10 February 2016 06:48:02 UTC
Original Document: http://v4.eir-parts.net/v4Contents/View.aspx?template=ir_material_for_fiscal_ym&sid=22195&code=4565